Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Bio-Techne stock has delivered a strong 44.2% return over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a premium rather than as an obvious bargain.
-
Over the last 12 months, Bio-Techne has returned 44.2%, which puts a clear spotlight on whether recent gains already reflect much of the good news in the price.
-
Expectations around Bio-Techne's ability to grow revenue and sustain healthy cash flows can support a higher valuation. However, any disappointment in execution or returns on new investment may weigh heavily on what investors are willing to pay.
-
Bio-Techne scores 0 out of 6 on our valuation checks , which suggests the stock currently leans expensive rather than offering clear value across the broader tests.
The issue now is whether Bio-Techne's current share price leaves enough margin of safety given what the intrinsic value estimate and valuation checks are signaling.
Does Bio-Techne Look Pricey on Cash Flow?
The Discounted Cash Flow (DCF) model uses projected future cash flows to estimate what Bio-Techne might be worth today. For Bio-Techne, the model is built on last twelve month free cash flow of about $252.5 million in $ and assumes that cash flows continue growing over time rather than shrinking.
Based on these assumptions, the DCF model points to an intrinsic value of about $59 per share. That sits below the current share price, which implies the market is pricing in richer expectations than the cash flow forecast supports. The DCF output indicates the stock is about 21.4% overvalued, so investors are paying a premium for Bio-Techne relative to this cash flow based estimate.
Overall, the DCF workup suggests Bio-Techne stock currently screens as overvalued rather than offering a clear margin of safety.
Our Discounted Cash Flow (DCF) analysis suggests Bio-Techne may be overvalued by 21.4%. Discover 49 high quality undervalued stocks or create your own screener to find better value opportunities.
Does Bio-Techne Look Pricey on Earnings?
P/E is usually a straightforward quick check for a profitable company like Bio-Techne because it ties the share price directly to current earnings.
Bio-Techne currently trades on a P/E of about 102.3x, which is well above the Life Sciences industry average of roughly 36.6x and also above the peer average of about 83.2x. This indicates that investors are willing to pay a much higher price for each dollar of Bio-Techne's earnings compared with many other companies in the same space.
The fair P/E ratio from the model is close to 26.9x. This is far below the present market multiple, and the model is heavily penalising the stock on this framework. This large gap is better read as a warning flag that Bio-Techne screens as very expensive on earnings, rather than as a precise target level for the P/E to revert to.
On the P/E multiple, Bio-Techne stock currently screens as clearly overvalued.
See what the numbers say about this price — find out in our valuation breakdown.
The Bio-Techne Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Bio-Techne pick up where this valuation puzzle leaves off and explain what sort of future growth, margins and earnings would need to occur for the stock to appear much cheaper or more expensive than today's share price. Each one links its number to a clear view on how Bio-Techne's growth, profitability and risks might evolve, which you can revisit as new information comes through on the Community page.
The community is split on Bio-Techne, with one side focused on product momentum and the other on deal risks and funding pressure.
Bull case: roughly fairly valued
"With 80% of revenue from recurring consumables, including recent partnerships in high-value diagnostic biomarkers and a sharpened focus on portfolio diversification through targeted M&A, Bio-Techne is uniquely positioned to compound both revenue and free cash flow growth as healthcare and research spending expand with a rising global, aging population and increased demand for complex, personalized medicine solutions…"
Read the full Bull Case to see why Bio-Techne could be undervalued
Bear case: 27% overvalued
"Prolonged downturn in biotech funding, evidenced by a more than 40% year-over-year decline, is dampening innovation and procurement from smaller biotech customers, a significant end market for Bio-Techne, and this could constrain both top-line revenue growth and margin expansion if the trend continues…"
Read the full Bear Case to see why Bio-Techne could be overvalued
Do you think there's more to the story for Bio-Techne? Head over to our Community to see what others are saying!
The Bottom Line
Both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiple view suggest that Bio-Techne stock is overvalued, with a wide gap between the current price and what the models indicate is reasonable. The broader valuation checks are also weak, which reinforces the idea that the share price already reflects optimistic assumptions. For you as an investor, the key consideration now is whether Bio-Techne can deliver the growth and returns on new investment that would support this premium, or whether expectations eventually reset closer to the intrinsic value estimate.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TECH .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
